Effects of oral contraceptives on bone mineral density

Treatments in Endocrinology

Volumn 3, Issue 3, 2004, Pages 191-196

  Gambacciani, Marco ^a   Monteleone, Patrizia ^a   Ciaponi, Massimo ^a   Sacco, Alessandro ^a   Genazzani, Andrea R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; AMENORRHEA; ANOVULATION; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; ESTROGEN DEFICIENCY; FEMALE; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; OLIGOMENORRHEA; OSTEOLYSIS; OSTEOPOROSIS; OVARY FUNCTION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; REVIEW; SPINE FRACTURE;

BONE DENSITY; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PREMENOPAUSE;

EID: 2642579000     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403030-00006     Document Type: Review

References (74)

1. Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91: 12-5
2. Bachrach LK. Malnutrition, endocrinopathies and deficits in bone mass acquisition. In: Bonjour JP, Tsang RC, editors. Nutrition and bone development. Philadelphia (PA): Lippincott-Raven, 1999: 262-77
3. Bland R. Steroid hormone receptor expression and action on bone. Clin Sci 2000; 98: 217-40
4. Ernst M, Heath JK, Rodan GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor 1, and parathyroid hormone stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989; 125: 825-33
5. Qu Q, Perlala-Heape M, Kapanen A, et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 1998; 22: 201-9
6. Jilka RL. Cytokines, bone remodelling, and estrogen deficiency: a 1998 update. Bone 1998; 23: 75-81
7. Girasole G, Jilka RL, Passeri G, et al. 17β-estradiol inhibits interleukin-6 production by bone-marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the anti-osteoporotic effect of estrogens. J Clin Invest 1992; 89: 883-91
8. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoblasts. J Exp Med 1997; 186: 489-95
9. Ott SM. Attainment of peak bone mass. J Clin Endocrinol Metab 1990; 71: 1082a-c
10. Geusens P, Dequeker J, Verstraeten A, et al. Age-, sex-, and menopause-related changes of femur and peripheral bone: population study using dual and single photon absorptiometry and radiogrammetry. J Nucl Med 1986; 27: 1504-9
11. Riggs BL, Wahner HW, Dunn WL, et al. Differential changes in bone mineral density of the appendicular and axial skeleton with ageing. J Clin Invest 1981; 67: 328-35
12. Gambacciani M, Spinetti A, De Simone L, et al. The relative contributions of menopause and aging to postmenopausal vertebral osteopenia. J Clin Endocrinol Metab 1993; 77 (11): 48-52
13. Hergenroeder AC. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr 1995; 126: 683-9
14. Bowman BM, Miller SC. Elevated progesterone during pseudopregnancy may prevent bone loss associated with low estrogen. J Bone Miner Res 1996; 11: 15-21
15. Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576-8
16. Chen L, Foged NT. Differentiation of osteoblast in vitro is regulated by progesterone. J Tongji Med Univ 1996; 16: 83-6
17. Kasperk CH, Wakley GK, Hierl T, et al. Gonadal and adrenal androgens are potent regulators of human bone metabolism in vitro. J Bone Miner Res 1997; 12: 464-71
18. Klibanski A, Biller BMK, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988; 67: 124-30
19. Biller BMK, Coughlin JF, Saxe V, et al. Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 1991; 78: 996-1001
20. Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass and bone loss: a prospective study of pre-, peri-, postmenopausal women. J Clin Invest 1996; 97: 14-21
21. Steinberg KK, Freni-Titulaer LW, De Puey EG, et al. Sex steroids and bone density in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988; 69: 533-9
22. Berga S, Mortola J, Girton L, et al. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 1989; 68: 301-8
23. Biller BMK, Federoff H, Koenig J, et al. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin Endocrinol Metab 1990; 70: 311-7
24. Suh B, Liu J, Berga S, et al. Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab 1988; 66: 733-9
25. Canalis E. Mechanisms of glucocorticoid action in bone implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81: 3441-7
26. Morris H, Need A, O'Loughlin P, et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990; 45: 305-8
27. Hattersley A, Meeran K, Burrin J, et al. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int 1994; 54: 198-202
28. Urena P, Iida-Klein A, Kong X, et al. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS17/2.8 and OK cells. Endocrinology 1994; 134: 451-6
29. Haenggi W, Casez J-P, Birkhaeuser MH, et al. Bone mineral density in young women with long-standing amenorrhea: limited effect of hormone replacement therapy with ethinylestradiol and desogestrel. Osteoporos Int 1994; 4: 99-103
30. Rencken M, Chestnut C, Drinkwater B. Bone density at multiple skeletal sites in amenorrheic athletes. JAMA 1996; 276: 238-40
31. Glastre C, Braillon P, David L, et al. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990; 70: 1330-3
32. Theintz G, Buchs D, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-5
33. Warren M, Brooks-Gunn J, Fox R, et al. Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight-bearing bones. J Clin Endocrinol Metab 1991; 72: 847-53
34. Warren MP, Brooks-Gun J, Fox RP, et al. Osteopenia in exercise-associated amenorrhea using ballet dancers as a model: a longitudinal study. J Clin Endodrinol Metab 2002; 87 (7): 3162-8
35. Recker RR, Davies KM, Hinders SM, et al. Bone gain in young adult women. JAMA 1992 Nov 4; 268 (17): 2403-8
36. Mazess RB, Barden HS. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills. Am J Clin Nutr 1991 Jan; 53 (1): 132-42
37. Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 1986 Oct; 34 (4): 333-40
38. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, et al. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002 Jun; 65 (6): 407-10
39. Prior JC, Kirkland SA, Joseph L, et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ 2001 Oct 16; 165 (8): 1023-9
40. Coenen CM, Thomas CM, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996 Mar; 53 (3): 171-6
41. Polatti F, Perotti F, Filippa N, et al. Bone mass and long-term monophasic oral contraceptive-treatment in young women. Contraception 1995; 51 (4): 221-4
42. Cromer BA. Effects of hormonal contraceptives on bone mineral density. Drug Saf 1999 Mar; 20 (3): 213-22
43. Cundy T, Cornish J, Roberts H, et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998; 92: 569-73
44. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13-6
45. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996; 129: 671-6
46. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG 2001 Dec; 108 (12): 1214-21
47. Gbolade B, Ellis S, Murby B, et al. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998; 105: 790-4
48. Paiva LC, Pinto-Neto AM, Faundes A. Bone density amongst long term users of medroxyprogesterone acetate as a contraceptive. Contraception 1998; 58: 351-5
49. Jeppsson S, Gershagen S, Johansson EDB, et al. Serum medroxyprogesterone (MPA), sex hormone binding globulin, gonadal steroids, gonadotropins and prolactin in women during long term use of depo-MPA as a contraceptive. Acta Endocrinol 1982; 99: 339-43
50. De Cree C, Lewin R, Ostyn M. Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea. Int J Sports Med 1988 Jun; 9 (3): 187-92
51. Cumming D. Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Arch Intern Med 1996; 156: 2193-1025
52. Hergenroeder AC, Smith EO, Shypailo R, et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am J Obstet Gynecol 1997; 176: 1017-25
53. Castelo-Branco C, Vicente JJ, Pous F, et al. Bone mineral density in young hypothalamic oligoamenorrheic women treated with oral contraceptives. J Reprod Med 2001; 46 (10): 875-9
54. Grinspoon S, Miller K, Coyle C, et al. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea. J Clin Endocrinol Metab 1999; 84 (6): 2049-55
55. Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa. JAMA 1991; 265: 1133-8
56. Klibanski A, Biller BMK, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995; 80: 898-904
57. Munoz MT, Morande G, Garcia-Centenara JA, et al. The effects of estrogen administration on bone mineral density in adolescents with anorexia nervosa. Eur J Endocrinol 2002; 146 (1): 45-50
58. Gambacciani M, Spinetti A, Gallo R, et al. Ultrasonographic bone characteristics during normal pregnancy: longitudinal and cross-sectional evaluation. Am J Obstet Gynecol 1995; 173 (3 Pt 1): 890-3
59. Rodin A, Murby B, Smith MA, et al. Perimenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women. Bone 1990; 11: 1-5
60. Nilas L, Christiansen C. The pathophysiology of peri- and postmenopausal bone loss. Br Obstet Gynaecol 1989; 96: 580-7
61. Gambacciani M, Spinetti A, Taponeco F, et al. Bone loss in perimenopausal women: a longitudinal study. Maturitas 1994; 18: 191-7
62. Perrone G, Galoppi P, Capri O, et al. Lumbar and femoral bone density in perimenopausal women with irregular cycles. Int J Fertil Menopausal Stud 1995; 3: 120-5
63. Wallach S, Henneman P. Prolonged estrogen therapy in postmenopausal women. JAMA 1959; 171: 1637-41
64. Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987; 156: 1347-56
65. Gambacciani M, Spinetti A, Cappagli B, et al. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation: effects on bone mineral density and metabolism. Maturitas 1994; 19: 125-31
66. Gambacciani M, Spinetti A, Taponeco F, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994 Mar; 83 (3): 392-6
67. Gambacciani M, Ciaponi M, Cappagli B, et al. Longitudinal evaluation of perimenopausal femoral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Osteoporos Int 2000; 11: 544-8
68. Kritz-Silverstein D, Barrett-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 1993; 83: 100-2
69. Gambacciani M, Cappagli B, Ciaponi M, et al. Hormone replacement therapy in perimenopause: effect of a low-dose oral contraceptive preparation on bone quantitative ultrasound characteristics. Menopause 1999; 6 (1): 43-8
70. O'Neill TW, Silman AJ, Naves Diaz M, et al. Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. Osteoporos Int 1997; 7: 72-8
71. Mallmin H, Ljunghall S, Persson J, et al. Risk factors for fractures of the distal forearm: a population based case-control study. Osteoporos Int 1994; 4: 298-304
72. O'Neill TW, Marsden D, Adams JE, et al. Risk factors, falls, and fractures of the distal forearm in Manchester, UK. J Epidemiol Community Health 1996; 50: 288-92
73. Cooper C, Hannaford F, Croft P, et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993; 14: 41-5
74. Michaëlsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and risk of hip fractures: a case-control study. Lancet 1999; 353: 1481-4